Tesetaxel

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC

The Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors

Phase II Study of Tesetaxel in Metastatic Melanoma

Capecitabine/Tesetaxel Versus Capecitabine/Placebo as Second-line Therapy for Gastric Cancer

Tesetaxel in Chemotherapy-naive Patients With Progressive, Castration-resistant Prostate Cancer

Tesetaxel for Previously Treated Patients With Bladder Cancer

Tesetaxel Every 3 Weeks vs Weekly vs Capecitabine as 1st-line Therapy for Locally Advanced or Metastatic Breast Cancer

Tesetaxel as Second-line Therapy for Patients With Advanced Gastric Cancer

Study of Tesetaxel in Japanese Patients With Solid Tumors

Tesetaxel as Second-line Therapy for Patients With Advanced Melanoma and Normal Serum LDH